ArticleScientific reports2026
Safety evaluation of a ketamine-dodecyl maltoside combination using angiogenesis and embryonic development models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine (KET) exhibits potential anticancer activity, with enhanced cytotoxicity against melanoma cells when combined with the permeation enhancer dodecyl maltoside (DDM). To support clinical translation, this study evaluated the embryotoxicity, effects on angiogenesis, and cytocompatibility of KET, DDM, and their combination (KET + DDM) using a chicken embryo model. The chorioallantoic membrane (CAM) assay was used to assess angiogenesis following treatment with KET (1000 µM), DDM (19.6 µM), or KET + DDM in fertilized eggs. Embryonic survival and morphology were monitored for five days. Quantitative PCR analysis of heart, lung, kidney, and brain tissues evaluated apoptosis-related genes (Caspase 3, Caspase 8, Caspase 9, BAX) and VEGF expression. Cytocompatibility was examined in primary embryonic fibroblasts (EFBs) using AlamarBlue assays and morphological assessment. The results showed no significant differences in vascular density, vessel length, or branching in the CAM assay across all treatments. Embryos treated with KET or KET + DDM showed normal survival and morphology, while DDM alone reduced viability. Apoptotic and angiogenic gene expression remained unchanged in major organs. In vitro, KET and KET + DDM did not reduce EFB viability or alter morphology. Overall, KET and KET + DDM did not produce detectable adverse effects in embryonic and cellular models, preserving angiogenesis and development. Notably, the KET + DDM combination showed no detectable adverse effects, supporting the preliminary safety of this combination for further anticancer investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.